IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

Monoclonal antibodies are an efficacious therapy against SARS-CoV-2. However, rapid viral mutagenesis, led to escape from most of these therapies, outlining the need for an antibody cocktail with a broad neutralizing potency. Using an unbiased interrogation of the memory B cell repertoire of convale...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikitin, Pavel A., DiMuzio, Jillian M., Dowling, John P., Patel, Nirja B., Bingaman-Steele, Jamie L., Heimbach, Baron C., Henriquez, Noeleya, Nicolescu, Chris, Polley, Antonio, Sikorski, Eden L., Howanski, Raymond J., Nath, Mitchell, Shukla, Halley, Scheaffer, Suzanne M., Finn, James P., Liang, Li-Fang, Smith, Todd, Storm, Nadia, McKay, Lindsay G. A., Johnson, Rebecca I., Malsick, Lauren E., Honko, Anna N., Griffiths, Anthony, Diamond, Michael S., Sarma, Purnanand, Geising, Dennis H., Morin, Michael J., Robinson, Matthew K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273042/
https://www.ncbi.nlm.nih.gov/pubmed/35771946
http://dx.doi.org/10.1126/sciimmunol.abl9943

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273042/
https://www.ncbi.nlm.nih.gov/pubmed/35771946
http://dx.doi.org/10.1126/sciimmunol.abl9943

Ejemplares similares